Akorn’s consolidated revenue for fourth quarter 2013 increases 19 percent to $85 million Akorn, Inc. , a niche generic pharmaceutical company, reported financial outcomes for the fourth quarter and year-ended December 31 today, 2013. Raj Rai, CEO commented, ‘2013 was a pivotal calendar year for Akorn http://sildenafilsa.com/kamagra-a-new-competitor-of-viagra-and-cialis.html . As a total result of investment in our product sales infrastructure and new product launches, we grew our business by over 20 percent year-over-year. Furthermore, we announced the prepared acquisition of Hi-Tech and finished acquisitions that extended our branded ophthalmic portfolio. We expect 2014 to become a transformational yr as we evolve into a well diversified organization, with a number of specific niche market dosage forms, and a commercial system to start novel ophthalmic formulations through acquisitions and partnerships.’ 2013 Key Highlights and Accomplishments Accomplished record year-end consolidated revenue of $317.7 million, a rise of 24 percent over the last year.
‘The development of fast, low cost, molecular diagnostic assessments for make use of in near point-of-care configurations has the potential to change the way CSF infections are identified,’ says Kevin Banking institutions, Ph.D., Vice President of Sales and Advertising at Akonni Biosystems. ‘Combining RT-PCR with this proprietary gel-drop microarray system in a self-included micro-fluidic chamber will additional enhance our ability to develop and deploy multi-check panels to affordably and rapidly detect viruses, bacteria, fungi and parasites in one patient sample.’.. Akonni to develop closed RT-PCR microarray for virus detection in CSF amplicon Akonni Biosystems, a molecular diagnostics firm that develops novel nucleic acid extraction and microarray-based testing systems made to rapidly and economically analyze biological samples, today announced receipt of a $300K grant from the National Institutes of Wellness .